Prochlorperazine Maleate
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00433 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 54 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | retinal dystrophy with or without extraocular anomalies | KG + DL |
| 2 | hydranencephaly (disease) | KG + DL |
| 3 | congenital disorder of glycosylation with defective fucosylation | KG + DL |
| 4 | myopia X-linked | KG + DL |
| 5 | Charcot-Marie-Tooth disease, demyelinating, type 1G | KG + DL |
| 6 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | KG + DL |
| 7 | syndromic myopia | KG + DL |
| 8 | myopia 26, X-linked, female-limited | KG + DL |
| 9 | atypical glycine encephalopathy | KG + DL |
| 10 | manic bipolar affective disorder | KG + DL |
| 11 | distal 17p13.3 microdeletion syndrome | KG + DL |
| 12 | hydrops-lactic acidosis-sideroblastic anemia-multisystemic failure syndrome | KG + DL |
| 13 | bipolar disorder | KG + DL |
| 14 | schizophreniform disorder | KG + DL |
| 15 | attention deficit hyperactivity disorder, inattentive type | KG + DL |
| 16 | major affective disorder | KG + DL |
| 17 | attention deficit-hyperactivity disorder | KG + DL |
| 18 | psychotic disorder | KG + DL |
| 19 | Phelan-McDermid syndrome | KG + DL |
| 20 | early-onset schizophrenia | KG + DL |
| 21 | specific developmental disorder | KG + DL |
| 22 | treatment-refractory schizophrenia | KG + DL |
| 23 | Malan overgrowth syndrome | KG + DL |
| 24 | REM sleep behavior disorder | KG + DL |
| 25 | faciodigitogenital syndrome | KG + DL |
| 26 | psychosexual disorder | KG + DL |
| 27 | chondromyxoid fibroma | KG + DL |
| 28 | trichotillomania | KG + DL |
| 29 | mental disorder | KG + DL |
| 30 | tic disorder | KG + DL |
| 31 | autism susceptibility 1 | KG + DL |
| 32 | enuresis | KG + DL |
| 33 | dissociative disorder | KG + DL |
| 34 | autism spectrum disorder | KG + DL |
| 35 | factitious disorder | KG + DL |
| 36 | childhood apraxia of speech | KG + DL |
| 37 | asperger syndrome, susceptibility to | KG + DL |
| 38 | gaze palsy, familial horizontal, with progressive scoliosis | KG + DL |
| 39 | striatal degeneration, autosomal dominant | KG + DL |
| 40 | skeletal overgrowth-craniofacial dysmorphism-hyperelastic skin-white matter lesions syndrome | KG + DL |
| 41 | neurodevelopmental disorder with or without hyperkinetic movements and seizures, autosomal recessive | KG + DL |
| 42 | postpartum psychosis | KG + DL |
| 43 | amelocerebrohypohidrotic syndrome | KG + DL |
| 44 | substance-induced psychosis | KG + DL |
| 45 | communication disorder | KG + DL |
| 46 | stereotypic movement disorder | KG + DL |
| 47 | fetal nicotine spectrum disorder | KG + DL |
| 48 | developmental disorder of mental health | KG + DL |
| 49 | Tourette syndrome | KG + DL |
| 50 | benign paroxysmal torticollis of infancy | KG + DL |
(Showing top 50 of 54 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.